Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ExoFlo
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : DB-001 (ExoFlo) is a regenerative medicine product candidate, designed to leverage the anti-inflammatory, immunomodulatory and regenerative properties of bone marrow MSC-derived EVs. Currently in development for medically refractory perianal fistulizing ...
Brand Name : DB-001
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
April 26, 2023
Lead Product(s) : ExoFlo
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ExoFlo
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : DB-001 (ExoFlo) is a regenerative medicine product candidate, designed to leverage the anti-inflammatory, immunomodulatory and regenerative properties of bone marrow MSC-derived EVs. Currently in development for treating severe or critical COVID-19.
Brand Name : DB-001
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
April 19, 2023
Lead Product(s) : ExoFlo
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ExoFlo
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : DB-001 (ExoFlo) is a regenerative medicine product candidate, designed to leverage the anti-inflammatory, immunomodulatory and regenerative properties of bone marrow MSC-derived EVs. Currently in development for treating severe or critical COVID-19.
Brand Name : DB-001
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
March 21, 2023
Lead Product(s) : ExoFlo
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ExoFlo
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : DB-001 (ExoFlo) is a regenerative medicine product candidate, designed to leverage the anti-inflammatory, immunomodulatory and regenerative properties of bone marrow MSC-derived EVs. Currently in development for treating severe or critical COVID-19.
Brand Name : DB-001
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
March 14, 2023
Lead Product(s) : ExoFlo
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ExoFlo
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Good Works II Acquisition Corp.
Deal Size : $75.0 million
Deal Type : Agreement
Details : ExoFlo received regenerative medicine advanced therapy (“RMAT”) designation for the treatment of severe or critical COVID-19 from the U.S. Food and Drug Administration (“FDA”).
Brand Name : DB-001
Molecule Type : Cell and Gene therapy
Upfront Cash : $75.0 million
October 13, 2022
Lead Product(s) : ExoFlo
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Good Works II Acquisition Corp.
Deal Size : $75.0 million
Deal Type : Agreement
Lead Product(s) : DB-001
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ExoFlo is an extracellular signal product isolated from human bone marrow MSCs that contains growth factors and extracellular vesicles including exosomes, to treat Acute Respiratory Distress Syndrome due to Covid-19.
Brand Name : ExoFlo
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
April 21, 2022
Lead Product(s) : DB-001
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : DB-001
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ExoFlo provides signaling proteins that have been shown to modulate inflammation and may stimulate bioactivity and direct cellular communication.
Brand Name : ExoFlo
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
June 29, 2021
Lead Product(s) : DB-001
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : DB-001
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ExoFlo is an investigational new drug that has not been approved or licensed by FDA. It is an extracellular vesicle product isolated from human bone marrow mesenchymal stem or stromal cells (MSCs).
Brand Name : ExoFlo
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
December 30, 2020
Lead Product(s) : DB-001
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : DB-001
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Recipient : Bioclinica
Deal Size : Undisclosed
Deal Type : Partnership
Details : Under the terms of the agreement, Direct Biologics will leverage Bioclinica’s Interactive Response Technology (IRT) for their EXIT COVID-19 study, a multi-center FDA phase II clinical trial for the use of ExoFlo™ to treat COVID-19 acute respiratory d...
Brand Name : ExoFlo
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
September 09, 2020
Lead Product(s) : DB-001
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Recipient : Bioclinica
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : DB-001
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Direct Biologics Initiates Patient Enrollment in the Phase II EXIT COVID-19 Clinical Trial
Details : EXIT COVID-19 has initiated enrollment of 75 COVID-19 patients with moderate-to-severe ARDS at multiple research sites across the U.S. The primary efficacy endpoints will be all-cause mortality and median days to recovery.
Brand Name : ExoFlo
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
September 09, 2020
Lead Product(s) : DB-001
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?